Systematic screening identified patients with an iron refractory iron deficiency anaemia (IRIDA) phenotype and genotype in iron-deficient children in the Indian subcontinent. Cases of moderate to severe microcytosis and anaemia with no obvious cause and normal C-reactive protein, HbA 2 and tissue transglutaminase antibody levels (n = 550) were put on a trial of oral iron for 4 weeks. Sixty of these 550 cases (11%) were variably refractory to oral iron therapy (<10 g/l Hb rise) at 4-6 weeks and were subsequently evaluated for plasma iron, ferritin and hepcidin levels. The mean age of this cohort was 2.06 years. Low-normal to normal ferritin and normal to high hepcidin levels were noted in 25/60 (41.6%) and 47/60 (78.3%), respectively. An IRIDA phenotype was noted in 38.3% (23/60) based on standard criteria. TMPRSS6 gene sequencing in 20 cases with IRIDA phenotype revealed 9 potentially deleterious intronic and two benign exonic variations in 12/20 cases (60%). Of these, 4 intronic and both exonic variations were noted in multiple cases and are likely to act synergistically leading to an IRIDA phenotype. However, given that only 38% (23/60 cases) of cases with iron refractoriness had IRIDA phenotype, a balanced approach is needed and other causes for refractoriness should be investigated before genetic studies for TMPRSS6 are undertaken.
Iron deficiency anaemia (IDA) is a major public health problem in the Indian subcontinent, with World Health Organization (WHO) data suggesting a prevalence of 60-70% in young children and pregnant females (Kapil & Bhadoria, 2014) . As a result, most children presenting with microcytic hypochromic anemia end up receiving oral iron trial without systematic investigation. This has led to physicians now having to tackle oral iron refractoriness more often. Moreover, the recent recognition of iron refractory iron deficiency anaemia (IRIDA) as a new genetically linked entity, the same, now needs to be considered in any systematic approach to diagnosis. The IRIDA genotype involves mutation in the TMPRSS6 gene on chromosome 22qc, encoding the type II serine protease, transmembrane protease, serine 6 (TMPRSS6; also termed matriptase-2) a negative regulator of hepcidin transcription. Hepcidin is a circulatory hormone that is responsible for the inhibition of duodenal iron absorption and macrophage iron recycling when body iron is replete (Knutson et al, 2005) . TMPRSS6 is responsible for the repression of hepcidin when body iron stores are depleted. Any loss of function mutation in TMPRSS6 leads to elevated hepcidin levels and hence iron absorption is hampered. This is also the reason why patients with IRIDA do not respond to oral iron supplements. However, key features of the IRIDA phenotype include varying degrees of anaemia, moderate-severe microcytosis, oral iron refractoriness, low serum iron, low-normal (lower end of normal range) to normal serum ferritin and inappropriately high hepcidin levels for the degree of anaemia (De Falco et al, 2010; Heeney & Finberg, 2014; Keskin & Yenicesu, 2015) . The frequency of IRIDA phenotype and the underlying gene variations is currently not known but is likely to have been under diagnosed or mis-diagnosed until now, especially in our setting. We believe that it is important to systematically evaluate and define this phenotype in an irondeficient endemic cohort so that genetic screening for TMPRSS6 gene variations can be cost effectively undertaken in a resource constraint setting.
Materials and methods
The methodology is summarized as a flow chart in Fig 1. Patients were recruited for the study based on routine reports. Control samples were selected from individuals with a normal blood report. Patients were enrolled following the receipt of written and informed consent from them or their parents/guardians. Blood from samples taken for routine diagnostic testing was used for research purposes i.e., no additional blood samples were drawn. Plasma iron and ferritin levels were elucidated by chemilumniscence assay and hepcidin by a sandwich enzyme linked immunosorbent assay. The normal paediatric ranges for hepcidin in our subcontinent are yet to be established. Hence for our study, 45 control samples were processed to define normal range of hepcidin, which was determined as 9.54-36.6 ng/ml.
The IRIDA phenotype was defined as described by De Falco et al (2013) . Anaemia was classified as mild (Hb 100-109 g/l), moderate (Hb 70-99 g/l) or severe (Hb <70 g/l) (WHO 2011). Microcytosis was classified as moderate (mean cell volume [MCV] 60-69 fl) or severe (MCV <60 fl) (Simmons, 1997) . The paediatric reference range for ferritin (6-110 lg/l) was adapted from Ashley (2012) to define low normal (6-11.9 lg/l) and normal (12-110 lg/l) values for the current study.
All 18 exons of TMPRSS6 were amplified using polymerase chain reaction (PCR) method in cases satisfying the IRIDA phenotype definition based on plasma iron, ferritin and hepcidin levels as described above (see Tables S1 and S2 for PCR primers and conditions). The amplified products were run on 2% agarose gel to verify amplification. PCR amplicon products were purified using ExoSAP-IT â (Affymetrix, Santa Clara, CA, USA). Sanger sequencing of purified product of each of the exons in all cases was performed on ABI 3500dx/3130 automated sequencing platform (Applied Biosystems, Carlsbad, CA, USA). The resulting chromatogram files were analysed using the Automated Sanger Analysis Pipeline (ASAP) developed in house by us (Singh & Bhatia, 2016) . Variations were manually curated for quality assurance from chromatogram files before reporting. They were then mapped on to the chromosome 22 of human genome assembly GRch 37 as this is the one used by the Single Nucleotide Polymorphism Database (dbSNP) (Sherry et al, 2001 ) and the 1000Genomes Project (The 1000 Genomes Project Consortium 2015), PolyPhen2 (Adzhubei et al, 2013) was used to ascertain the effects of exonic variation. The RNA features were found using regulatory RNA (RegRNA) (Chang et al, 2013 ) and compared with the wild type sequence. Discrete categorical data is presented either numerically or as a percentage (%). The normality of quantitative data was checked by KolmogorovSmirnov tests. Means for all haematological and biochemical parameters of both the initial and final cohorts were compared using a two-sided Student's t test at a significance level of a = 0.05. Analysis was 
Results
A total of 550 paediatric cases with variable degrees of anaemia and moderate to severe microcytosis were initially enrolled and put on a trial of oral iron. The response to conventional iron dosage at 4-6 weeks was assessed and 60/550 cases (11%) were found to be refractory to oral iron therapy. These 60 cases did not have any obvious cause for anaemia based on detailed history and examination and had normal C-reactive protein (CRP), tissue transglutaminase antibody (tTGA) and HbA 2 levels. This subset of cases was further evaluated to determine the frequency of the IRIDA phenotype. The mean age of children enrolled for evaluation of IRIDA phenotype and genotype (n = 60) was 2.2 years with a range of 6 months to 11 years. The cohort included 46 boys (76.7%) and 14 girls (23.3%) with a male to female ratio of 3.2:1. Fifty-three children (88.3%) were normal weight and height, 6 children (10%) had failed to thrive and 1 child (1.7%) was overweight. All 60 children were attaining developmental milestones normally but clinically, had pallor. Three out of 60 children (5%) had angular cheilitis. Other clinical features of severe iron deficiency, such as hair changes, dry skin and koilonychia, were not observed in any of the children. The haematological and biochemical parameters are highlighted in Table I .
Twenty-three children (38.3%) had IRIDA phenotype (low Hb, low MCV and MCH, very low-low iron, low-normal to normal ferritin and inappropriate, i.e. normal to high, hepcidin levels). The mean age of cases with IRIDA phenotype was 2.02 years (range 0.6-7.). The male:female ratio was 10.5:1 with 21 (91%) boys and 2 (9%) girls. Table I summarises the laboratory features of cases with and without IRIDA phenotype.
On comparison between means of various parameters in cohort of patients with (n = 23) and without (n = 37) IRIDA phenotype, it was noted that those with IRIDA phenotype had slightly better mean haemoglobin and less severe anaemia (Hb 82 vs. 72 g/l). In addition, all cases with IRIDA phenotype had very low or low plasma iron and none had near normal/normal levels (mean 0.96 vs. 1.25 lmol/l). The mean plasma ferritin was in the normal range for cases with IRIDA as compared to those without IRIDA phenotype (40.24 vs. 2.8 lg/l) and mean plasma hepcidin was in the high normal range (28.8 vs. 17.0 ng/ml). The last two differences were expected to be significant because low-normal to normal plasma ferritin and normal to high hepcidin levels are included in the standard criteria used to define IRIDA phenotype.
Sequencing data results were available in 20/23 cases due to non-consent in the others, and revealed a total of 65 genetic variations of TMPRSS6 in 12/20 (60%) cases. These included 15 exonic and 50 intronic variations. Out of 15 exonic variations, 11 were synonymous variations (i.e. non functional without amino acid change/silent variations). However, 2 were non-synonymous exonic variations (P555S and V736A), seen in three cases (P555S in 1 case, V736A in 1 case and both in 1 case): PolyPhen2 scores suggest that these variations are "benign" in that they are not likely to severely affect TMPRSS6 function. Of the 50 intronic variations, only 9 were potentially deleterious as per RegRNA analysis. However, 4 of these intronic variations were seen in multiple cases. These intronic genetic variations involved transcriptional regulatory motifs in 5 cases (1 of them [g.23404T>A] was common to 4 cases), untranslated region (UTR) binding element loss in 4 cases (g.25335T>C, common to all 4 cases), C to U RNA editing site generation in 5 cases (g.35000C>T, common to all 5 cases), exon splicing silencer insertion in 3 cases (g.11184A>G, common to all 3 cases) and splice site shift, cryptic splice site generation and loss of intronic splicing enhancer site in 1 case each. Hence, 9 potentially deleterious intronic variations and 2 benign exonic variations (total 11) were seen in 12/20 (60%) cases (see Fig 2 and Tables II and III) . The variations were either homozygous or compound heterozygous in 11/12 cases thus fulfilling the genetic criteria for defining the autosomal recessive nature of IRIDA. Only one case had a heterozygous genetic intronic variation. In a further search of the 1000 Genome database (www.1000genomes.org) for these variations, 8/11 could be mapped as known polymorphisms with a variable minor allele frequency (MAF). Three of these variations, 23404T>A, 42484G>T and 40632T>A, were novel and intronic in nature, with the former being present in 4 cases (see Tables II & III and Figs S1and S2 ).
Discussion
Our study points to a relatively high prevalence of IRIDA phenotype (38%) amongst 60 children with anaemia refractory to oral iron and suggests that this condition could have been mis-or under-diagnosed until now. This is one of the first studies from the Indian subcontinent to highlight the prevalence of IRIDA phenotype based on serum levels of ferritin Iron and hepcidin. In our cohort of patients with IRIDA phenotype, plasma ferritin was normal in 56.5% and low-normal in 43.5%, whilst plasma hepcidin was high in 30% and within normal range in 70%. In the initial case series on IRIDA described by Finberg et al (2008) all 7 probands with the TMPRSS6 mutation had normal ferritin and high hepcidin levels. Akin et al (2014) studied a cohort of 11 children with oral iron refractoriness. The mean age of children in their study was 4.8 years with a mean Hb of 77 g/l at presentation. However, the mean ferritin in their study was low-normal, at around 4.8 lg/l. Moreover, Akin et al (2014) defined the IRIDA phenotype loosely, as plasma hepcidin levels were not performed in any of their cases.
A substantial proportion of cases (62%) in our cohort had unexplained oral iron refractoriness without fulfilling the IRIDA Phenotype and TMPRSS6 Gene Variations ª 2017 John Wiley & Sons Ltd standard criteria for IRIDA phenotype. Causes for unexplained oral iron refractoriness when compliance-related issues have been ruled out include Helicobacter pylori infection, coeliac disease and autoimmune gastritis. Eleven of these 37 cases in our study (29.7%) had both low ferritin and hepcidin, consistent with classical iron deficiency anaemia. These cases would have probably responded to better attention to compliance issues, extended oral iron therapy or change in iron formulation. Twenty-four of these 37 cases (64.9%) had low ferritin and normal to high hepcidin levels. This suggests a phenotype of anaemia of chronic disease: however, we had ruled this out by assessing CRP levels. H. pylori has been implicated in several studies as a cause of IDA refractory to oral iron treatment in the last decade or so along with a favourable response to increase in Hb following its eradication (Hershko et al, 2007; Hershko & Skikne, 2009) . It has been shown that 55% of the adult cases with iron deficiency anaemia harboured H. pylori infection and were refractory to oral iron therapy; their anaemia improved after treatment for H. pylori infection (Hershko & Camaschella, 2014) . The relationship between H. pylori infection and paediatric refractoriness to oral iron therapy has not yet been well studied or established and needs to be assessed in a cohort of such cases. Coeliac disease has been shown to account for 5-6% of unexplained IDA cases and approximately 50% of patients with subclinical coeliac disease are known to develop IDA (Hershko & Skikne, 2009) . Autoimmune gastritis has also been suggested to be associated with development of chronic idiopathic IDA due to the possible role of H. pylori infection in its pathogenesis: it has been shown that iron deficiency in autoimmune gastritis tends to develop many years before the depletion of vitamin B12 stores (Hershko & Skikne, 2009 ). Although single case reports of low ferritin with normal/high hepcidin levels have also been associated with IRIDA (Silvestri et al, 2009; Sato et al, 2011; Lehmberg et al, 2012 ) the literature is scanty and the current criteria for IRIDA only includes cases with lownormal to normal levels of ferritin. The remaining 2 out of the 37 cases (5.4%) had normal ferritin and low hepcidin values, suggesting a possible thalassaemia phenotype. As b- thalassaemia had been excluded by using high performance liquid chromatography and normal HbA 2 levels, the possibility of an a-thalassaemia carrier state in these cases is high considering the higher prevalence of the same in our region. In our study, genetic sequencing of TMPRSS6 in 20/23 cases with IRIDA phenotype revealed high frequencies of multiple intronic and or exonic variations in single cases, including 9 potentially deleterious intronic and 2 "benign" exonic variations in 12/20 (60%) cases. The current pilot study is one of the few studies, and the first from Indian sub-continent in the paediatric age group. TMPRSS6 polymorphisms have recently gained recognition as a more common predisposing factor for the development of IDA and or IRIDA phenotype in many genome wide association studies (GWAS) from different ethnic populations (Benyamin et al, 2009; Chambers et al, 2009; An et al, 2012; Gan et al, 2012; McLaren et al, 2012; Galesloot et al, 2013) . Though most exonic variations (11) in our study were silent or synonymous, two (g.38612 C>T [P555S]; g.42668T>C [V736A]) were common single nucleotide polymorphisms (SNPs) widely described in the literature as predisposing to anaemia and low iron status. In a systematic review and meta analysis of TMPRSS6 gene polymorphisms Wainaina et al (2015) the rs855791 (V736A) polymorphism had a 0.42), with the A variant being associated with a slightly lower Hb and serum ferritin levels. The V736A polymorphism was present in two cases with IRIDA phenotype in our study, one case with Hb 77 g/l and ferritin 7.2 lg/l while the other had an Hb of 97 g/l and ferritin of 108 lg/l. Though the V736A polymorphism may negatively influence iron store repletion, thereby modifying the degree of anaemia and oral iron response, the final clinical phenotype, Hb and ferritin levels in our two cases could have been further influenced by the other potentially deleterious intronic variations present in both these cases (see Table III ). Multiple, potentially deleterious, intronic variations were very common in our IRIDA phenotype cohort with 4 of 9 variations being seen in up to 5/12 cases (Table III , Fig S2) . The review article by Keskin and Yenicesu (2015) listed all of the studies reported to date regarding cases with iron refractory iron deficiency phenotype but having a heterozygous TMPRSS6 mutation. The combined effect of these multiple heterozygous or homozygous intronic and/or exonic genetic changes in the TMPRSS6 gene within single cases in our study can very likely explain the IRIDA phenotype. Moreover, the importance of non-coding genetic variations in development of various complex traits and human disease and cancer is also well known and recognized, and is described in recent reviews on the subject (Ward & Kellis, 2012; Khurana et al, 2016) . Iron metabolism involves a complex interplay of many genes involved in the absorption, transfer, utilization and storage of iron in the body. Hence it is likely that the various phenotypes related with iron deficiency or IRIDA-like features could be due to an additive effect of variations in noncoding regions of underlying genes like TMPRSS6 and others like HAMP (encoding hepcidin) or HFE2 (encoding haemojuvelin; also termed HVJ). In a study from the Indian subcontinent (Athiyarath et al, 2015) , next generation sequencing (NGS) was performed for 9 iron-related genes in 5 pregnant females with anaemia who had failed to respond to oral iron supplement. The authors identified many rare and a few novel variants in the iron metabolism related genes with the P555S SNP in TMPRSS6 (also present in 2 cases in our study) and many potentially deleterous intronic variations in TF (encoding transferrin), TRF2 (transferrin receptor 2), SLC11A2 and HAMP, findings that are consistent with the high frequency of intronic variations in our ethnic population predisposing to the IDA/IRIDA-like phenotype. The authors also concluded that the synergistic effect of these intronic variations on anaemia could not be overlooked (Athiyarath et al, 2015) . In addition to the above genetic findings, it was also interesting to note that the 11 synonymous exonic variations in our study were, in fact, 3 different variations occurring in a total of seven cases. The g.42678C>T in exon 17 was seen in 2 cases and g.36013C>T in exon 13 and g.24807G>A in exon 9 in 4 cases each ( Fig  S2) . The contribution of synonymous variations in diseases with complex phenotype has been highlighted (Sauna & Sarfaty, 2011) . The above authors, on the basis of previous studies showing this association, concluded that synonymous variations can cause change in protein expression, conformation and function primarily via protein mis-folding (Sauna & Sarfaty, 2011) . Another recent review (Diederichs et al, 2016) highlighted the role of non coding region and synonymous variations in the development of cancer. Iron metabolism is a complex phenomenon and is likely to be affected by such multiple genetic variations in both exonic and or intronic region of genes that interact closely to maintain iron homeostasis in the body. Regarding the correlation of genetic variations in our study with underlying phenotypic features, it was noted that all of these cases were boys (P = 0.000) and 8/12 (67%) were aged <2 years. The majority of these cases (67%) had moderate anaemia and severe microcytosis (58%). No response to oral iron was noted in 3/12 cases while 5/12 had partial 1+ response (1.0 to 4.0 g/l rise in Hb). Seven of the 12 (58%) cases had normal ferritin levels and 3/12 (25%) had hepcidin levels higher than the normal range. Another interesting relationship noted was that all three cases with severe IRIDA phenotype and underlying genetic variations had UTR element binding loss as one of the intronic variation, together with hepcidin levels higher than normal range. However, further functional characterization of these rare and novel genetic variations seen in the TMPRSS6 gene are needed to better define the differential mechanisms of iron regulation in cases with IDA and/or IRIDA phenotype. Further evaluation of our study cohort is planned with screening of their family members/siblings for underlying variations after obtaining written informed consent. In addition, the 12 cases with genetic variations will be offered therapy with intravenous iron and followed up for response or continued on long term oral iron challenge, especially those with mild anaemia. However, GWAS are needed in a large sample of our population to identify and define the frequency of TMPRSS6 and other iron-related gene polymorphisms. Moreover, queries arising from our study, such as why all of the cases affected with genetic variations are male in present study, although a recent report has shown that more females were affected in an IRIDA cohort (Donker et al, 2016) , needs to be investigated in larger prospective studies. Do other genetic factors related with ethnicity in our region affect iron-related genes or are some trans-acting genes or factor(s) on the X-chromosome responsible for this phenotype? What is the genetic abnormality in the other 8/20 cases with IRIDA phenotype in our study? Is mutational analysis of HAMP or genes encoding proteins involved in hepcidin secretion, such as BMP6 and HFE2, needed? This and more on the multiple and recurring nature of TMPRSS6 variations in single cases needs to be analysed in larger prospective studies employing NGS tools.
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